Archives
IgA Nephropathy – From Pathogenesis to Current Management
About This Event
IgA Nephropathy – From Pathogenesis to Current Management
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation, diagnosis, prognosis, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression.
Copper Canyon Grill
Featuring
Kimberly Means, PharmD, BCCCP, BSN, RN
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Kimberly Means, PharmD, BCCCP, BSN, RN, is a Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Means earned her B.S. in Nursing (BSN) and her Doctor of Pharmacy (PharmD) from Virginia Commonwealth University (VCU) in Richmond, Virginia. She completed a PGY-1 Pharmacy Practice Residency and a PGY-2 Critical Care Residency at VCU Health in Richmond, Virginia. Prior to joining Otsuka, she worked as a critical care nurse at VCU Health, a Critical Care Clinical Pharmacist at Henrico Doctors’ Hospital, and a Clinical Pharmacist in Surgical Services at VCU Health. During her time as a Clinical Assistant Professor at the VCU School of Pharmacy and VCU Health she served as a preceptor for pharmacy students and pharmacy residents. Dr Means is a Board Certified Critical Care Pharmacotherapy Specialist (BCCCP).
Kimberly Means, PharmD, BCCCP, BSN, RN is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
